{"id":602905,"date":"2026-09-01T19:40:14","date_gmt":"2026-09-01T19:40:14","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/602905\/"},"modified":"2026-09-01T19:40:14","modified_gmt":"2026-09-01T19:40:14","slug":"gprc5d-targeting-bispecific-and-trispecific-antibodies-in-multiple-myeloma-current-evidence-and-emerging-strategies","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/602905\/","title":{"rendered":"GPRC5D-targeting bispecific and trispecific antibodies in multiple myeloma: Current evidence and emerging strategies"},"content":{"rendered":"<p>Review<\/p>\n<p>. 2026 Sep 1;132(17):e70597.<\/p>\n<p>        doi: 10.1002\/cncr.70597.<\/p>\n<p>    Affiliations<\/p>\n<p>        Expand<\/p>\n<p>            Affiliation<\/p>\n<p>              1 Department of Medicine, University of California, San Francisco, California, USA.<\/p>\n<p>\n  Item in Clipboard\n<\/p>\n<p>Review<\/p>\n<p>        Darren Pan\u00a0et al.<\/p>\n<p>        Cancer.<\/p>\n<p>          2026.<\/p>\n<p>            Show details<\/p>\n<p>    Display options<\/p>\n<p>\n      Display options\n    <\/p>\n<p>            Format<\/p>\n<p>  Abstract<\/p>\n<p>  PubMed<\/p>\n<p>  PMID<\/p>\n<p>. 2026 Sep 1;132(17):e70597.<\/p>\n<p>        doi: 10.1002\/cncr.70597.<\/p>\n<p>            Affiliation<\/p>\n<p>              1 Department of Medicine, University of California, San Francisco, California, USA.<\/p>\n<p>\n  Item in Clipboard\n<\/p>\n<p>CiteDisplay options<\/p>\n<p>\n      Display options\n    <\/p>\n<p>\n            Format<br \/>\n          AbstractPubMedPMID<\/p>\n<p>        Abstract<\/p>\n<p>      G-protein-coupled receptor class C group 5 member D (GPRC5D) has emerged as a crucial immunotherapy target in relapsed\/refractory multiple myeloma. Although the T-cell-engaging bispecific antibody talquetamab is currently the only approved anti-GPRC5D therapy, numerous promising agents are undergoing clinical evaluation. While anti-GPRC5D chimeric antigen receptor T cells show potential, this review focuses specifically on T-cell-engaging bispecific and trispecific antibodies. We highlight how GPRC5D differs clinically from B-cell maturation antigen, explore mechanisms of resistance, discuss novel therapeutic strategies including combination regimens and talquetamab as bridging therapy to chimeric antigen receptor T cells, and review key investigational T-cell engagers currently in development.\n    <\/p>\n<p>          Keywords:<\/p>\n<p>      CAR\u2010T cells; GPRC5D; T\u2010cell engagers; bridging; combination therapy; immunotherapy; relapsed refractory multiple myeloma.\n    <\/p>\n<p class=\"copyright\" id=\"copyright\">\n    \u00a9 2026 American Cancer Society. All rights reserved, including rights for text and data mining and training of artificial intelligence technologies or similar technologies.\n  <\/p>\n<p class=\"disclaimer\" id=\"disclaimer\">\n  <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/disclaimer\/\" target=\"_blank\" data-ga-category=\"literature_resources\" data-ga-action=\"disclaimer_link\" data-ga-label=\"under_abstract\" rel=\"nofollow noopener\">PubMed Disclaimer<\/a>\n<\/p>\n<p>      References<\/p>\n<p>            Rodriguez\u2010Otero P, van de Donk NW, Pillarisetti K, et al. GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review. Blood Cancer J. 2024;14(1):24. doi:10.1038\/s41408\u2010023\u201000966\u20109<\/p>\n<p>            Li J, Stagg NJ, Johnston J, et al. Membrane\u2010proximal epitope facilitates efficient T cell synapse formation by anti\u2010FcRH5\/CD3 and is a requirement for myeloma cell killing. Cancer Cell. 2017;31(3):383\u2010395. doi:10.1016\/j.ccell.2017.02.001<\/p>\n<p>            Pillarisetti K, Edavettal S, Mendon\u00e7a M, et al. A T\u2010cell\u2013redirecting bispecific G\u2010protein\u2013coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. Blood. 2020;135(15):1232\u20101243. doi:10.1182\/blood.2019003342<\/p>\n<p>            Atamaniuk J, Gleiss A, Porpaczy E, et al. Overexpression of G protein\u2010coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. Eur J Clin Invest. 2012;42(9):953\u2010960. doi:10.1111\/j.1365\u20102362.2012.02679.x<\/p>\n<p>            Cohen Y, Gutwein O, Garach\u2010Jehoshua O, Bar\u2010Haim A, Kornberg A. GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells. Hematology. 2013;18(6):348\u2010351. doi:10.1179\/1607845413y.0000000079<\/p>\n<p>      Show all 60 references<\/p>\n<p>        MeSH terms<\/p>\n<p>      Antibodies, Bispecific* \/ pharmacology<\/p>\n<p>      Antibodies, Bispecific* \/ therapeutic use<\/p>\n<p>      Multiple Myeloma* \/ drug therapy<\/p>\n<p>      Multiple Myeloma* \/ immunology<\/p>\n<p>      Multiple Myeloma* \/ therapy<\/p>\n<p>      Receptors, G-Protein-Coupled* \/ antagonists &amp; inhibitors<\/p>\n<p>      Receptors, G-Protein-Coupled* \/ immunology<\/p>\n<p>      T-Lymphocytes \/ immunology<\/p>\n<p>        Substances<\/p>\n<p>      Receptors, G-Protein-Coupled<\/p>\n<p>    [x]<\/p>\n<p>Cite<\/p>\n<p>      Copy<\/p>\n<p>\n  Format:<\/p>\n<p>        AMA<\/p>\n<p>        APA<\/p>\n<p>        MLA<\/p>\n<p>        NLM<\/p>\n","protected":false},"excerpt":{"rendered":"Review . 2026 Sep 1;132(17):e70597. doi: 10.1002\/cncr.70597. Affiliations Expand Affiliation 1 Department of Medicine, University of California, San&hellip;\n","protected":false},"author":2,"featured_media":602906,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[272539,2594,9936,272538,272540,272541,114,272537,272536,272546,272547,11030,85,272542,46,105233,272543,272544,272545,265087,17587,109162,92402,15304,265086,272535,265085,50538,1529,272548],"class_list":["post-602905","post","type-post","status-publish","format-standard","has-post-thumbnail","category-business","tag-ajai-chari","tag-animals","tag-antibodies","tag-anupama-kumar","tag-bispecific-pharmacology","tag-bispecific-therapeutic-use","tag-business","tag-darren-pan","tag-doi10-1002-cncr-70597","tag-g-protein-coupled-antagonists-inhibitors","tag-g-protein-coupled-immunology","tag-humans","tag-il","tag-immunotherapy-methods","tag-israel","tag-medline","tag-multiple-myeloma-drug-therapy","tag-multiple-myeloma-immunology","tag-multiple-myeloma-therapy","tag-national-center-for-biotechnology-information","tag-national-institutes-of-health","tag-national-library-of-medicine","tag-ncbi","tag-nih","tag-nlm","tag-pmid42675812","tag-pubmed-abstract","tag-receptors","tag-review","tag-t-lymphocytes-immunology"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/602905","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=602905"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/602905\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/602906"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=602905"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=602905"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=602905"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}